The Business Development group introduces R+D projects in a First World Biotechnological strategy, promoting the venture capital investment and placing Heber Biotec S.A. as a partner for developed countries companies.

Heber Biotec shows increasing export levels, our suppliers have been preparing for the challenge of the regulatory requirement of the most stringent international markets. Today the Center for Genetic Engineeringand Biotechnology, The Placental Histotherapy Center, The Chemical Bioactive Products Center and AICA, NOVATEC and Liorad laboratories, structured in an strategic alliance of the West Havana Scientific Pole, allows Heber Biotec to maintains its leader position among the Biotechnology enterprises in Cuba.

Heber Biotec S.A. figure today among the who pre-qualified suppliers of the recombinant HB vaccine (Heberbiovac HB) for UNICEF, OPS and other United Nations agencies or institutions that requires this quality standard certification in the products.The main objectives of the Heber Biotec quality system are the customer satisfaction and the continuous improvement for the fast growing biotechnology and pharmaceutical markets. Our company is prepared to face the challenges of continuously offering higher standard of quality based in a extent program for the development and introduction of new products and applications.